Similarly, Seifert et al. found that while Lu-PSMA-617 therapy frequently controls liver metastases, the hepatic tumor burden did not appear to influence treatment efficacy, suggesting that Lu-PSMA-617 is effective even in patients with substantial liver involvement [15]. This evidence concerns the gene FOLH1 and medical procedure.